One in six
In four years, GLP-1 prescribing among women with PMOS (PCOS) went from a rarity to routine. If you feel like everyone's suddenly on one, you're not imagining it — and the evidence is finally catching up to the trend.
A quick note before we start
We're writers, not doctors, and this is general information — not medical advice. A trend being popular doesn't make it right for you, and a medication being right for you doesn't depend on how many other people are taking it. Take this to an appointment, not as one. Carrying on.
Here's a number worth sitting with. Among women with PMOS (PCOS), the share being prescribed semaglutide or tirzepatide climbed from 2.4% in 2021 to 17.6% in 2025 — a more than sevenfold jump in four years. Roughly one in six now. If it feels like the conversation flipped overnight from "have you tried losing weight" to "have you tried a GLP-1," that's because, statistically, it did.
We find that shift worth watching carefully — not cheering, not warning, just watching. A surge that fast is usually part real progress and part hype, and the honest work is telling which part is which.
What's actually driving it
The real part first. PMOS (PCOS) is, at its core, a metabolic condition — insulin resistance sits underneath a lot of the weight, the irregular cycles, and the frustration of diets that never seem to work. GLP-1 medications act on exactly that machinery. In real-world data drawn largely from semaglutide, women with PCOS saw a median body weight reduction of about 11.5% at one year. And in a small study, around 71% of the women who responded to semaglutide got back to regular menstrual cycles within six months. For a condition where "just eat less" has been the standard non-answer for decades, a medication that addresses the underlying metabolism is a genuinely different tool.
For a condition treated for decades with "just eat less," a drug that acts on the actual metabolism is a different kind of tool.
The part the headline leaves out
Now the caution. As of 2026, no GLP-1 is FDA-approved specifically for PMOS (PCOS). These are being used off-label — legitimately and commonly, but off-label — and the evidence base, while growing, is still thinner than the prescribing volume would suggest. Three independent studies landed within a single twelve-month window, and a Phase 3 PCOS trial is recruiting. That's real momentum. It is not the same as a settled, indication-specific approval.
There's a nuance here that keeps getting flattened. "GLP-1s" get talked about as if they're one drug. They aren't. Tirzepatide produces more weight loss in the broad obesity population, so it's easy to assume it's the obvious PCOS pick — but there are almost no dedicated tirzepatide-for-PCOS trials yet. Semaglutide, by contrast, is where most of the PCOS-specific evidence actually sits. So the better-studied choice for this condition and the biggest-number choice for general weight loss aren't necessarily the same molecule. That's the kind of detail worth raising with a provider rather than assuming.
What this looks like as a question, not a bandwagon
If you're weighing whether to join the one-in-six, a few things are fair to put to your clinician: Is the specific drug you're recommending backed by PCOS evidence, or by general weight-loss evidence extended to me? What are we actually treating — the weight, the insulin resistance, the cycles, or all three? And how will we know it's working beyond the scale? A provider who treats PMOS (PCOS) as the metabolic condition it is will have real answers, not just a prescription pad.
That's the whole reason we keep the comparison: a rising trend is only good news if it lands you with someone who sees the condition clearly. Popular and right-for-you are different questions, and you deserve both answered.
The quiet part
For a lot of women, the hardest thing about this surge isn't deciding whether to try a medication — it's grieving the years spent being told the problem was your willpower when it was your physiology all along. Both things can be true: the tool is real, and the long wait to be taken seriously was unfair. You're allowed to feel the relief and the anger. We do.
The honest disclaimer. This is general information from the women who write Selene — not medical advice, not a recommendation, and not a promise of what will happen for you. PMOS (PCOS) treatment is individual and clinical; please make those decisions with a licensed clinician who knows your history, not with a website. Selene is editorial — we don't prescribe, sell, or dispense anything. GLP-1 medications are not FDA-approved specifically for PMOS (PCOS), and are not a treatment for endometriosis.